Pfizer selects WS for Exubera work

NEW YORK: Pfizer is working with Weber Shandwick to launch Exubera, the first inhalable insulin for both juvenile and adult-onset diabetes.

NEW YORK: Pfizer is working with Weber Shandwick to launch Exubera, the first inhalable insulin for both juvenile and adult-onset diabetes.

The Food and Drug Administration approved Exbera last month, and Pfizer is planning a mid-year launch for the product.

Rebecca Hamm, Pfizer's director of PR said that there would be a heavy educational focus. The drug giant currently abides by a self-imposed moratorium on direct-to-consumer advertising during the first six months that a product is on the market. Pfizer reformed its advertising guidelines in August in order to devote more time to educating doctors about a drug's risks and benefits ahead of a consumer launch.

Hamm noted that the Exubera campaign would adhere to those new principles.

She added that 21 million Americans have diabetes, and 95% have type 2 diabetes, the adult-onset form.

Hamm noted that Exubera improves on the way insulin is delivered, reducing or eliminating the need for injections.

"There's definitely a fear of needles as well as the pain the injections might bring," she said.

 

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Would you like to post a comment?

Please Sign in or register.